Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials

Funding led by Paragon Biosciences, joined by Fidelity Management &Research Company LLC and Valor Equity Partners CHICAGO, March 23, 2021 -- (Healthcare Sales &Marketing Network) -- Emalex Biosciences, Inc. ("Emalex"), a biopharmaceutical c... Biopharmaceuticals, Venture Capital Emalex Biosciences, ecopipam
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Clinical Trials | Funding | Marketing | Pharmaceuticals | Stammer | Tourette Syndrome | Venture Capital